What is Zacks Research's Forecast for Avantor Q2 Earnings?

Avantor, Inc. (NYSE:AVTR - Free Report) - Analysts at Zacks Research cut their Q2 2026 earnings estimates for Avantor in a research report issued on Wednesday, February 5th. Zacks Research analyst D. Dey now expects that the company will post earnings per share of $0.28 for the quarter, down from their prior forecast of $0.29. The consensus estimate for Avantor's current full-year earnings is $0.98 per share.

Avantor (NYSE:AVTR - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 EPS for the quarter, beating analysts' consensus estimates of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same period last year, the business earned $0.22 EPS.

A number of other equities analysts have also issued reports on the stock. Stifel Nicolaus dropped their target price on shares of Avantor from $28.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday. Raymond James reaffirmed an "outperform" rating and set a $24.00 target price (down previously from $26.00) on shares of Avantor in a research report on Monday. UBS Group reaffirmed a "neutral" rating and set a $25.00 target price (down previously from $29.00) on shares of Avantor in a research report on Friday, January 17th. Royal Bank of Canada dropped their target price on shares of Avantor from $33.00 to $31.00 and set an "outperform" rating on the stock in a research report on Monday. Finally, Robert W. Baird dropped their target price on shares of Avantor from $27.00 to $26.00 and set an "outperform" rating on the stock in a research report on Monday, October 28th. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, Avantor currently has an average rating of "Moderate Buy" and a consensus target price of $26.15.

Avantor Stock Performance

Shares of NYSE:AVTR traded up $0.07 during trading on Monday, reaching $18.12. The stock had a trading volume of 6,265,783 shares, compared to its average volume of 5,451,938. Avantor has a 52 week low of $17.90 and a 52 week high of $28.00. The firm has a market capitalization of $12.33 billion, a price-to-earnings ratio of 39.38, a P/E/G ratio of 3.87 and a beta of 1.28. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. The stock has a fifty day simple moving average of $21.57 and a two-hundred day simple moving average of $23.35.

Institutional Investors Weigh In On Avantor

Several institutional investors and hedge funds have recently made changes to their positions in the company. CANADA LIFE ASSURANCE Co boosted its stake in shares of Avantor by 5.8% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 1,012,692 shares of the company's stock valued at $21,338,000 after purchasing an additional 55,481 shares in the last quarter. Canada Pension Plan Investment Board boosted its stake in shares of Avantor by 0.5% in the 4th quarter. Canada Pension Plan Investment Board now owns 21,037,089 shares of the company's stock valued at $443,251,000 after purchasing an additional 112,644 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Avantor in the 4th quarter valued at $203,000. Dodge & Cox raised its holdings in shares of Avantor by 44.9% in the fourth quarter. Dodge & Cox now owns 99,145,770 shares of the company's stock valued at $2,089,001,000 after buying an additional 30,727,673 shares during the last quarter. Finally, Broyhill Asset Management bought a new position in shares of Avantor in the fourth quarter valued at about $4,536,000. Institutional investors and hedge funds own 95.08% of the company's stock.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.